
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
(Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e) (2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to Section 240.14a-11 (c) or Section 240.14a-12

NEUBASE THERAPEUTICS, INC.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

No fee required.

Fee paid previously with preliminary materials.

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



P.O. BOX 8016, CARY, NC 27512-9903

**NeuBase Therapeutics, Inc.
Important Notice Regarding the Availability of
Proxy Materials for the Stockholders Meeting to
be Held on September 28, 2023
For Stockholders of Record as of
August 4, 2023**

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy materials, and to obtain directions to attend the meeting, go to: www.proxydocs.com/NBSE

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet.



**For a convenient way to view proxy materials and VOTE go to
www.proxydocs.com/NBSE**



Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions.

If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before September 18, 2023.

To order paper materials, use one of the following methods.


INTERNET
www.investorelections.com/NBSE


TELEPHONE
(866) 648-8133


*** E-MAIL**
paper@investorelections.com

When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.

* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

NeuBase Therapeutics, Inc.

Meeting Materials: Notice of Meeting, Proxy Statement and Annual Report on Form 10-K
Meeting Type: Annual Meeting of Stockholders
Date: Thursday, September 28, 2023
Time: 8:30 AM, Eastern Time
Place: Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/NBSE for more details.

You must register to attend the meeting online and/or participate at www.proxydocs.com/NBSE

SEE REVERSE FOR FULL AGENDA

NeuBase Therapeutics, Inc.

Annual Meeting of Stockholders

**THE BOARD OF DIRECTORS RECOMMENDS A VOTE:
FOR ON PROPOSALS 1, 2, 3 AND 4**

PROPOSAL

1. To elect one Class III director, nominated by our Board of Directors, to serve until our 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified;
1.01 Franklyn G. Prendergast, M.D., Ph.D.
 2. To ratify the selection of Marcum LLP ("Marcum") as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
 3. To conduct an advisory (non-binding) vote on executive compensation; and
 4. To approve an amendment and restatement of the Company's Amended and Restated Certificate of Incorporation, as amended, to reflect Delaware law provisions allowing officer exculpation.
-